Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular risks
Pharma
Novo's oral GLP-1 Rybelsus cuts heart disease risks
The FDA has accepted Novo Nordisk’s application for a label expansion for its oral GLP-1 drug Rybelsus to reduce the risk of cardiovascular events.
Kevin Dunleavy
Mar 31, 2025 11:30am
Silence Therapeutics gets loud in Lp(a) awareness campaign
Aug 29, 2024 8:30am
Novo Nordisk pulls Wegovy HF submission, will resubmit in 2025
Aug 7, 2024 10:30am
Bayer aspirin campaign links stress of sports to heart health
Feb 6, 2023 8:00am
